Literature DB >> 30046984

Successful Vaccines.

Ian J Amanna1, Mark K Slifka2.   

Abstract

Vaccines are considered one of the most important advances in modern medicine and have greatly improved our quality of life by reducing or eliminating many serious infectious diseases. Successful vaccines have been developed against many of the most common human pathogens, and this success has not been dependent upon any one specific class of vaccine since subunit vaccines, non-replicating whole-virus or whole-bacteria vaccines, and attenuated live vaccines have all been effective for particular vaccine targets. After completing the initial immunization series, one common aspect of successful vaccines is that they induce long-term protective immunity. In contrast, several partially successful vaccines appear to induce protection that is relatively short-lived and it is likely that long-term protective immunity will be critical for making effective vaccines against our most challenging diseases such as AIDS and malaria.

Entities:  

Year:  2018        PMID: 30046984      PMCID: PMC6777997          DOI: 10.1007/82_2018_102

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  144 in total

1.  Association of the chimpanzee coryza agent with acute respiratory disease in children.

Authors:  M BEEM; F H WRIGHT; D HAMRE; R EGERER; M OEHME
Journal:  N Engl J Med       Date:  1960-09-15       Impact factor: 91.245

2.  Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older--United States, 2016.

Authors:  David K Kim; Carolyn B Bridges; Kathleen H Harriman
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-02-05       Impact factor: 17.586

3.  Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.

Authors:  Steven Black; Leonard R Friedland; Anne Schuind; Barbara Howe
Journal:  Vaccine       Date:  2006-04-21       Impact factor: 3.641

4.  The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.

Authors:  Jay M Lieberman; Wendy R Williams; Jacqueline M Miller; Steven Black; Henry Shinefield; Frederick Henderson; Colin D Marchant; Alan Werzberger; Scott Halperin; Jonathan Hartzel; Stephanie Klopfer; Florian Schödel; Barbara J Kuter
Journal:  Pediatr Infect Dis J       Date:  2006-07       Impact factor: 2.129

5.  Haemophilus influenzae type b vaccines: lessons for the future.

Authors:  J I Ward; C V Broome; L H Harrison; H Shinefield; S Black
Journal:  Pediatrics       Date:  1988-06       Impact factor: 7.124

6.  Immunity to disease caused by Hemophilus influenzae type b. II. Specificity and some biologic characteristics of "natural," infection-acquired, and immunization-induced antibodies to the capsular polysaccharide of Hemophilus influenzae type b.

Authors:  R Schneerson; L P Rodrigues; J C Parke; J B Robbins
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

7.  Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP).

Authors:  Elizabeth C Briere; Lorry Rubin; Pedro L Moro; Amanda Cohn; Thomas Clark; Nancy Messonnier
Journal:  MMWR Recomm Rep       Date:  2014-02-28

8.  Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.

Authors:  Maria Rosario Capeding; Ngoc Huu Tran; Sri Rezeki S Hadinegoro; Hussain Imam H J Muhammad Ismail; Tawee Chotpitayasunondh; Mary Noreen Chua; Chan Quang Luong; Kusnandi Rusmil; Dewa Nyoman Wirawan; Revathy Nallusamy; Punnee Pitisuttithum; Usa Thisyakorn; In-Kyu Yoon; Diane van der Vliet; Edith Langevin; Thelma Laot; Yanee Hutagalung; Carina Frago; Mark Boaz; T Anh Wartel; Nadia G Tornieporth; Melanie Saville; Alain Bouckenooghe
Journal:  Lancet       Date:  2014-07-10       Impact factor: 79.321

9.  Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.

Authors:  Mark H Einstein; Myron J Levin; Archana Chatterjee; Nahida Chakhtoura; Peter Takacs; Grégory Catteau; Francis J Dessy; Philippe Moris; Lan Lin; Frank Struyf; Gary Dubin
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States.

Authors:  Shannon Stokley; Jenny Jeyarajah; David Yankey; Maria Cano; Julianne Gee; Jill Roark; Robinette C Curtis; Lauri Markowitz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-07-25       Impact factor: 17.586

View more
  7 in total

1.  Development of a next-generation chikungunya virus vaccine based on the HydroVax platform.

Authors:  Dawn K Slifka; Hans-Peter Raué; Whitney C Weber; Takeshi F Andoh; Craig N Kreklywich; Victor R DeFilippis; Daniel N Streblow; Mark K Slifka; Ian J Amanna
Journal:  PLoS Pathog       Date:  2022-07-05       Impact factor: 7.464

2.  Perspective Technologies of Vaccination: Do We Still Need Old Vaccines?

Authors:  Maria Isaguliants; Felicity Jane Burt
Journal:  Vaccines (Basel)       Date:  2022-06-02

3.  Public Knowledge, Beliefs and Attitudes toward the COVID-19 Vaccine in Saudi Arabia: A Cross-Sectional Study.

Authors:  E L Walid El Hassan; Amal Khaleel Abu Alhommos; Dalal Aliadhy; Shaima Alsalman; Ohoud Alnafaa; Ahmed Mohamed
Journal:  Healthcare (Basel)       Date:  2022-05-05

4.  Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine.

Authors:  Benjamin K Quintel; Archana Thomas; Danae E Poer DeRaad; Mark K Slifka; Ian J Amanna
Journal:  Vaccine       Date:  2018-12-31       Impact factor: 3.641

5.  Clinical-Pathological Conference Series from the Medical University of Graz : Case No. 164: A 46-year-old man with abdominal pain, dyspnea and rapidly progressing multiorgan failure.

Authors:  Elisabeth Fabian; Christoph Wenisch; Florian Eisner; Tina Muhr; Philipp K Bauer; Kurt Prein; Urša Maierhofer; Sigurd F Lax; Robert Krause; Gernot Zollner; Wolfgang Weihs; Guenter J Krejs
Journal:  Wien Klin Wochenschr       Date:  2021-04-19       Impact factor: 1.704

Review 6.  Precision Vaccine Development: Cues From Natural Immunity.

Authors:  Soumik Barman; Dheeraj Soni; Byron Brook; Etsuro Nanishi; David J Dowling
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

7.  Targeting Myeloid-Derived Suppressor Cells to Enhance a Trans-Sialidase-Based Vaccine Against Trypanosoma cruzi.

Authors:  Juan Cruz Gamba; Carolina Roldán; Estefanía Prochetto; Giuliana Lupi; Iván Bontempi; Carolina Verónica Poncini; Mónica Vermeulen; Ana Rosa Pérez; Iván Marcipar; Gabriel Cabrera
Journal:  Front Cell Infect Microbiol       Date:  2021-07-06       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.